Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Celldex Therapeutics (CLDX) was upgraded by Wolfe Research from "peer perform" to "outperform". They now have a $44.00 price target on the stock.
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year Return [Yahoo! Finance]
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts [Yahoo! Finance]
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference [Yahoo! Finance]